ERBB2 and neoplasm: A significant proportion of tumors in our study exhibited discordant HER2 status following treatment, with some HER2 IHC score 0 tumors exhibiting HER2 expression according to IHC after NAT, and some HER2-low tumors demonstrating HER2 IHC score 0 status in residual tumor cells.